The FDA has approved palbociclib (Ibrance) in combination with trastuzumab (Herceptin), endocrine therapy, and optionally ...

After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients ...

Hormone receptor status can affect treatment decisions ...

Backed by phase 3 PATINA trial data, Ibrance is the first and only CDK4/6 inhibitor available for HR+ metastatic disease across all HER2 patient profiles.

The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial ...

Today, Alliance Foundation Trials, LLC (AFT) was informed that the U.S. Food and Drug Administration has approved palbociclib ...

The FDA has approved the first and only cyclin-dependent kinase 4/6 inhibitor for patients with HR-positive metastatic breast cancer, regardless of HER2 status. Palbociclib (Ibrance, Pfizer) was ...

HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone-blocking treatments crucial. Diagnosis ...

FDA clearance establishes the first CDK4/6 inhibitor indication spanning HR+ metastatic disease regardless of HER2 status, creating a new maintenance strategy for HR+/HER2+ tumors. PATINA randomized ...

Discover how advancements in HER2-positive breast cancer treatment enhance patient outcomes through personalized therapies and innovative strategies for both early and metastatic stages. Over the past ...

Maintenance indication applies after response or stable disease following initial chemotherapy plus trastuzumab, with or without pertuzumab, in HR-positive, HER2-positive advanced breast cancer.

There is a promising shift toward nonsurgical treatment strategies in early breast cancer, as clinicians aim to reduce harm ...